Importantly, RUNX2-expressing tumours were expressed at a significantly higher rate in ER-negative (13/131; 10%) compared with ER-positive (9/281; 3%) breast cancers (Fig. 1C,D; P=0.005; chi-square test). Here, RUNX2 is linked to neoplasm.